Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05607550 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | PHASE3 | ACTIVE NOT_RECRUITING | 398 | — | — | Jun 1, 2023 | Feb 15, 2028 | Jun 22, 2025 | 208 | United States, Australia +17 |
| Arm | Type | Description |
|---|---|---|
| furmonertinib 240 mg | EXPERIMENTAL | - |
| furmonertinib 160 mg | EXPERIMENTAL | - |
| platinum-based chemotherapy | ACTIVE_COMPARATOR | carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously |
| Name | Type | Description |
|---|---|---|
| furmonertinib 240 mg oral, daily | DRUG | furmonertinib tablet |
| furmonertinib 160 mg oral, daily | DRUG | furmonertinib tablet |
| platinum-based chemotherapy | DRUG | (carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV) |
Key Inclusion Criteria: * Histologically or cytologically documented, locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. * Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion...